Fibrocell Science

03/31/2020

We’re excited to introduce you to Castle Creek Biosciences, Inc., our new page on Facebook! Soon, we’ll be retiring this page. Head over to our new page for all updates relating to company news and our clinical development pipeline. We’ll see you there!

12/16/2019

We’re excited to embark on this journey with Castle Creek and we look forward to what’s to come as one organization. This means that soon our social media pages will become retired. Be sure to follow -Creek-Pharmaceuticals on LinkedIn and Twitter () for future updates and news https://bit.ly/2YXc74X

12/16/2019

Today we announced that Fibrocell has officially been acquired by Castle Creek Pharmaceuticals to become one company focused on delivering new therapies for patient communities with high unmet need. See our press release

- Acquisition complements and expands Castle Creek clinical development pipeline to include gene therapy platform - - Strategic acquisition to result in advancement of multiple late-stage investigational therapies for epidermolysis bullosa and other rare conditions – Exton, PA., December 16, 2019 ...

12/04/2019

Honored to support the Rare Disease Legislative Advocates’ 8th Annual RareVoice Awards tonight in Washington, DC. This event recognizes & celebrates the tireless work of advocates in rare disease communities across the country. RDLA is a program of the EveryLife Foundation for Rare Diseases.

The RareVoice Awards is an annual celebration to honor advocates who give rare disease patients a voice on Capitol Hill and in state government. Patient advocates, industry executives, and Congressional and government agency staff gather to honor these outstanding advocates in the rare disease commu...

12/04/2019

Today, debra of America Exec Dir Brett Kopelan addresses “Developing Holistic Collaborations Between Advocates and Drug Developers” in epidermolysis bullosa at CBI’s Rare Disease Clinical Development & Access Summit in Arlington, VA. Agenda at

Explore Patient-Centric Approaches to Trial Design, Recruitment and Access to Enhanced Outcomes

11/20/2019

Today, Fibrocell Pres & CEO John Maslowski addresses development of personalized biologics for rare skin diseases, including RDEB and Localized Scleroderma, and the importance of advocacy groups at the 3rd Annual Dermatology Drug Development Summit in Boston. Event guide https://bit.ly/2O1aEqn

10/30/2019

Today, join Pres & CEO John Maslowski for an update on Fibrocell gene therapy candidate FCX-007 for RDEB as part of the EB Research Partnership Community Council webinar on Clinical Trials. Program begins at 6PM ET/3PM PT. Register https://www.ebresearch.org/community-council.html

10/29/2019

Proud to support EB Research Partnership's 10th Annual ACTion for Jackson Benefit on Nov 7 at the Mandarin Oriental in NYC from 6:30 – 9:30 pm. Proceeds support research focused on finding treatments and cures for EB. Get tickets, more info https://bit.ly/2q3S2fS

10/24/2019

On 10/30 at 3PM PT/6PM ET, join Fibrocell President & CEO John Maslowski to hear about the Company's FCX-007
gene therapy program for RDEB, as part of the EB Research Partnership's Community Council Clinical Trials
webinar. Learn more & egister at https://lnkd.in/ePyqaVf

10/23/2019

Congratulations to debra of America for presenting the inspiring & memorable 21st Annual debra Benefit that honors, celebrates, and provides support to the Epidermolysis Bullosa community. We Fight EB!!

10/21/2019

Tonight, proud to support the 21st Annual debra of America Benefit at Tribeca 360° in NYC. Join us at 6PM. http://debra.org/benefit

10/15/2019

On Mon, Oct 21, Alfred Lane, MD, chief medical advisor of Fibrocell, will be honored with a Lifetime Achievement Award at the 21st Annual debra of America Benefit at Tribeca 360° in NYC. Proceeds benefit people living with epidermolysis bullosa (EB), a painful, often fatal, and always debilitating rare genetic disease. Learn about the evening’s honorees and festivities, get tickets http://debra.org/benefit